

# Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease

Paul Elliott, FRCP

John C. Chambers, PhD

Weihua Zhang, PhD

Robert Clarke, MD

Jemma C. Hopewell, PhD

John F. Peden, PhD

Jeanette Erdmann, PhD

Peter Braund, MSc

James C. Engert, PhD

Derrick Bennett, PhD

Lachlan Coin, PhD

Deborah Ashby, PhD

Ioanna Tzoulaki, PhD

Ian J. Brown, PhD

Shahrul Mt-Isa, BSc

Mark I. McCarthy, FRCP

Leena Peltonen, MD, PhD

Nelson B. Freimer, MD

Martin Farrall, FRCPATH

Aimo Ruokonen, MD, PhD

Anders Hamsten, MD

Noha Lim, PhD

Philippe Froguel, MD

Dawn M. Waterworth, PhD

Peter Vollenweider, MD

Gerard Waeber, MD

Marjo-Riitta Jarvelin, MD

Vincent Mooser, MD

James Scott, FRS

Alistair S. Hall, FRCP

Heribert Schunkert, MD

Sonia S. Anand, MD

Rory Collins, FRCP

Nilesh J. Samani, FRCP

Hugh Watkins, FRCP

Jaspal S. Kooner, FRCP

See also pp 49 and 92.

**Context** Plasma levels of C-reactive protein (CRP) are independently associated with risk of coronary heart disease, but whether CRP is causally associated with coronary heart disease or merely a marker of underlying atherosclerosis is uncertain.

**Objective** To investigate association of genetic loci with CRP levels and risk of coronary heart disease.

**Design, Setting, and Participants** We first carried out a genome-wide association (n=17 967) and replication study (n=13 615) to identify genetic loci associated with plasma CRP concentrations. Data collection took place between 1989 and 2008 and genotyping between 2003 and 2008. We carried out a mendelian randomization study of the most closely associated single-nucleotide polymorphism (SNP) in the *CRP* locus and published data on other *CRP* variants involving a total of 28 112 cases and 100 823 controls, to investigate the association of *CRP* variants with coronary heart disease. We compared our finding with that predicted from meta-analysis of observational studies of CRP levels and risk of coronary heart disease. For the other loci associated with CRP levels, we selected the most closely associated SNP for testing against coronary heart disease among 14 365 cases and 32 069 controls.

**Main Outcome Measure** Risk of coronary heart disease.

**Results** Polymorphisms in 5 genetic loci were strongly associated with CRP levels (% difference per minor allele): SNP rs6700896 in *LEPR* (−14.8%; 95% confidence interval [CI], −17.6% to −12.0%;  $P=6.2 \times 10^{-22}$ ), rs4537545 in *IL6R* (−11.5%; 95% CI, −14.4% to −8.5%;  $P=1.3 \times 10^{-12}$ ), rs7553007 in the *CRP* locus (−20.7%; 95% CI, −23.4% to −17.9%;  $P=1.3 \times 10^{-38}$ ), rs1183910 in *HNF1A* (−13.8%; 95% CI, −16.6% to −10.9%;  $P=1.9 \times 10^{-18}$ ), and rs4420638 in *APOE-CI-CII* (−21.8%; 95% CI, −25.3% to −18.1%;  $P=8.1 \times 10^{-26}$ ). Association of SNP rs7553007 in the *CRP* locus with coronary heart disease gave an odds ratio (OR) of 0.98 (95% CI, 0.94 to 1.01) per 20% lower CRP level. Our mendelian randomization study of variants in the *CRP* locus showed no association with coronary heart disease: OR, 1.00; 95% CI, 0.97 to 1.02; per 20% lower CRP level, compared with OR, 0.94; 95% CI, 0.94 to 0.95; predicted from meta-analysis of the observational studies of CRP levels and coronary heart disease (z score, −3.45;  $P < .001$ ). SNPs rs6700896 in *LEPR* (OR, 1.06; 95% CI, 1.02 to 1.09; per minor allele), rs4537545 in *IL6R* (OR, 0.94; 95% CI, 0.91 to 0.97), and rs4420638 in the *APOE-CI-CII* cluster (OR, 1.16; 95% CI, 1.12 to 1.21) were all associated with risk of coronary heart disease.

**Conclusion** The lack of concordance between the effect on coronary heart disease risk of *CRP* genotypes and CRP levels argues against a causal association of CRP with coronary heart disease.

JAMA. 2009;302(1):37-48

www.jama.com

**C**ORONARY HEART DISEASE (CHD) is the leading cause of death worldwide.<sup>1</sup> Inflammation plays a key role in the pathogenesis of CHD at every stage from initiation to progression and rupture of the atherosclerotic plaque.<sup>2</sup> C-reactive protein (CRP), an acute-phase protein synthesized primarily by the liver, is currently the most widely used biomarker of inflammation.<sup>3</sup> Ob-

servational studies have consistently demonstrated that higher plasma levels of CRP are associated with higher risk of CHD,<sup>4,5</sup> and measurement of CRP has been advocated as a means of improving risk prediction.<sup>6</sup> There is

**Author Affiliations** are listed at the end of this article.  
**Corresponding Author:** Paul Elliott, FRCP, MRC-HPA Centre for Environment and Health, Department of Epidemiology and Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, United Kingdom (p.elliott@imperial.ac.uk).

considerable interest in whether CRP has a causal role in CHD<sup>7,8</sup> or whether CRP is merely a marker of underlying atherosclerosis. Although previous studies have addressed this question, it is unclear whether they included a sufficient number of cases to have adequate statistical power to confirm or refute associations of CHD with genetically determined differences in CRP levels.<sup>8</sup> Resolution of this question will improve understanding of inflammatory mechanisms in atherosclerosis.

The mendelian randomization concept has been used to investigate possible causal relationships of an intermediate trait (such as CRP levels) with disease, taking advantage of the random allocation of alleles at conception.<sup>9</sup> If the intermediate trait is causally linked to disease, then genetic variants influencing the trait should also influence disease risk.<sup>10</sup> Mendelian randomization studies should be unaffected by confounding from environmental factors, eg, smoking, and reverse causation bias, ie, where the disease itself (atherosclerosis) influences the trait (CRP levels).<sup>9</sup>

The aims of the present study were to conduct a genome-wide association study to identify common genetic variants associated with CRP levels and use mendelian randomization to improve understanding of the possible causal relationship of CRP levels with CHD.

## METHODS

### Study Design and Rationale

The study involved 4 interrelated components. First, a genome-wide association and replication study was performed to identify genetic loci associated with CRP levels, and at each locus, the most closely associated single-nucleotide polymorphism (SNP) was selected. Second, a mendelian randomization study for the most associated SNP in the *CRP* locus in our data together with published data on *CRP* variants with CHD let us assess the potential causal association of CRP with CHD. Third, we compared the finding from the mendelian randomization study with that predicted from meta-analysis of the relationship of CRP levels with CHD from observational stud-

ies. Fourth, we carried out genetic association between CHD and the most associated SNPs in genetic loci outside the *CRP* locus using the concept of CRP as an intermediate phenotype,<sup>10</sup> to identify putative pathways linking inflammation with CHD.

### Population Cohorts

**Genome-wide and Replication Study for CRP.** Genome-wide association to identify variants related to CRP levels, measured using high-sensitivity assays, was carried out in 17 967 participants from 5 studies: the London Life Sciences Population (LOLIPOP) study (n=5502), a population-based cohort of European and Indian Asian men and women aged 35 to 75 years and living in West London, United Kingdom<sup>11</sup> (data collection, 2001-2007; genotyping, 2003-2008); the 1966 Northern Finnish Birth Cohort (NFBC) (n=4761), a prospective birth cohort of persons born in 1966 in the 2 northernmost provinces of Finland<sup>12,13</sup> (data collection, 1997-1998; genotyping, 2007-2008); the Lausanne Cohort (CoLaus) (n=5226), a cross-sectional study of a random sample of European men and women aged 35 to 75 years and living in Lausanne, Switzerland<sup>14</sup> (data collection, 2003-2006; genotyping, 2006-2007); the Genetic Epidemiology of Metabolic Syndrome (GEMS) study (n=1781), a case-control study of dyslipidemic cases (age, 20-65 years) matched with normolipidemic controls by sex and recruitment site<sup>15</sup> (data collection, 2003-2006; genotyping, 2006-2007); and the Data from an Epidemiological Study on the Insulin Resistance syndrome (DESIR) study (n=697), a longitudinal French general population cohort of persons aged 30 to 64 years recruited through the French social security system<sup>16</sup> (data collection, 1994-2004; genotyping, 2006-2007). Replication of SNPs associated with CRP levels, identified in the genome-wide association study, was performed in a further 13 615 LOLIPOP participants who were not included in the genome-wide association study and were free of known CHD.

### Mendelian Randomization and Genetic Association Studies With CHD.

Variants related to CRP levels were tested for association with CHD among 14 365 CHD cases and 32 069 controls. The participating studies comprised the Precocious Coronary Artery Disease study (PROCARDIS) (n=8328), a case-control study of premature CHD before age 66 years<sup>17</sup> (data collection, 1999-2006; genotyping, 2008); the International Studies of Infarct Survival (ISIS) (n=3624), comprising men aged 30 to 54 years and women aged 30 to 64 years with nonfatal myocardial infarction (MI) and their spouse controls<sup>18,19</sup> (data collection, 1989-1992; genotyping, 2008); the British Heart Foundation Family Heart Study, comprising individuals with MI or coronary revascularization before the age of 66 years and at least 1 first-degree relative with premature CHD, who were also studied as part of the Wellcome Trust Case Control Consortium (WTCCC) (n=3249-4863)<sup>20</sup> (data collection, 1998-2006; genotyping, 2006-2008); the German MI Family Studies (GerMIFS I: n=2519; GerMIFS II: n=2520), comprising persons with MI before the age of 60 years and at least 1 first-degree relative with premature CHD and matched controls<sup>20,21</sup> (data collection, 1996-2008; genotyping, 2006-2008); the INTERHEART study, a multinational case-control study of persons presenting with first MI (n=4043),<sup>22</sup> (data collection, 1999-2003; genotyping, 2008); and the LOLIPOP study (n=20 475) (data collection, 2001-2007; genotyping, 2008).

### Genotyping

Genome-wide association scans were performed using the Affymetrix 500K mapping array (Affymetrix Inc, Santa Clara, California), the Illumina 317K array (Illumina Inc, San Diego, California), and Perlegen Sciences customized arrays (Perlegen Sciences Inc, Mountain View, California). To combine data across genotyping platforms, imputation was done using a hidden Markov model algorithm implemented in MACH version 1.0 (Center for Statistical Genetics, University of Michigan, Ann Arbor) (in LOLIPOP) or IMPUTE version 0.5.0 (Genetics Software Suite, University of Oxford, Oxford,

United Kingdom) (in other studies) and phased haplotypes from National Center for Biotechnology Information (NCBI) build 35, dbSNP build 125. For the European data sets, the HapMap CEU sample was used for reference haplotypes; Indian Asian data sets were imputed based on a combination (mixed) of HapMap populations. Imputed SNPs with minor allele frequency (MAF) less than 0.01 or a low-quality score ( $r^2 < 0.30$  in MACH or information score  $< 0.50$  in IMPUTE) were removed. This left approximately 1.4 million directly genotyped or imputed autosomal SNPs per participant with data available in all samples. Genotyping for replication testing and for evaluation against CHD was performed using KASPar (KBiosciences Ltd, Hoddesdon, Hertfordshire, United Kingdom) (in LOLIPOP), Sequenom (Sequenom Inc, San Diego) (in INTERHEART and PROCARDIS), TaqMan (Applied Biosystems, Foster City, California) (in ISIS and WTCCC), or Affymetrix mapping arrays (in GerMIFS I and II and WTCCC).


**Statistical Analyses**

**Genome-wide Association and Replication Study for CRP.** Genome-wide SNP associations for CRP were tested in

multiple linear regression analyses using an additive genetic model. CRP levels were log-transformed to achieve approximate normal distribution and analyzed as a quantitative trait with adjustment for age and sex (analysis of residuals showed good adherence to normality assumptions). To account for heterogeneity in population structure, principal compo-

nents derived from EIGENSTRAT version 2.0 (Reich Laboratory, Harvard University, Cambridge, Massachusetts) were included as covariates in age- and age-sex-adjusted analyses for CoLaus, GEMS, NFBC, and LOLIPOP Indian Asian Illumina analyses (the number of principal components included varied from 4 to 10, depending on the popula-

**Figure 1.** Manhattan Plot of Results From the Combined Analysis of Genome-Wide Association Data



The horizontal dotted line represents genome-wide significance ( $5 \times 10^{-8}$ ). The red dots are the most associated single-nucleotide polymorphism at each of the *LEPR*, *IL6R*, *CRP*, and *HNF1A* loci and the *APOE-CI-CII* cluster.

**Table 1.** Genomic Context, Alleles, Minor Allele Frequency, Association Test Results for Most Associated SNP at Each Locus, and Effect on CRP Levels<sup>a</sup>

|                                     | Single-Nucleotide Polymorphism |                       |                        |                        |                            |
|-------------------------------------|--------------------------------|-----------------------|------------------------|------------------------|----------------------------|
|                                     | rs6700896                      | rs4537545             | rs7553007              | rs1183910              | rs4420638                  |
| Genomic context                     |                                |                       |                        |                        |                            |
| Chromosome                          | 1                              | 1                     | 1                      | 12                     | 19                         |
| Position                            | 65862370                       | 152685503             | 157965173              | 119905190              | 50114786                   |
| Locus                               | <i>LEPR</i>                    | <i>IL6R</i>           | <i>CRP</i>             | <i>HNF1A</i>           | <i>APOE-CI-CII</i> cluster |
| Alleles                             |                                |                       |                        |                        |                            |
| Reference                           | C                              | C                     | G                      | C                      | A                          |
| Minor                               | T                              | T                     | A                      | T                      | G                          |
| Minor allele frequency <sup>b</sup> |                                |                       |                        |                        |                            |
| Europeans                           | 0.38                           | 0.43                  | 0.33                   | 0.32                   | 0.19                       |
| Indian Asians                       | 0.46                           | 0.31                  | 0.29                   | 0.39                   | 0.12                       |
| Genome-wide association             |                                |                       |                        |                        |                            |
| <i>P</i> value                      | $3.1 \times 10^{-14}$          | $1.8 \times 10^{-14}$ | $7.6 \times 10^{-44}$  | $1.2 \times 10^{-30}$  | $4.5 \times 10^{-27}$      |
| Replication                         |                                |                       |                        |                        |                            |
| CRP effect, % (95% CI) <sup>c</sup> | -14.8 (-17.6 to -12.0)         | -11.5 (-14.4 to -8.5) | -20.7 (-23.4 to -17.9) | -13.8 (-16.6 to -10.9) | -21.8 (-25.3 to -18.1)     |
| <i>P</i> value                      | $6.2 \times 10^{-22}$          | $1.3 \times 10^{-12}$ | $1.3 \times 10^{-38}$  | $1.9 \times 10^{-18}$  | $8.1 \times 10^{-26}$      |

Abbreviations: CI, confidence interval; CRP, C-reactive protein; SNP, single-nucleotide polymorphism.  
<sup>a</sup>Association tests based on National Center for Biotechnology Information (NCBI) build 36, dbSNP build 126.  
<sup>b</sup>Minor allele frequency from people genotyped in replication sample.  
<sup>c</sup>Effect size is % change and 95% confidence interval in CRP per copy of minor allele under an additive genetic model adjusted for age, sex, and ethnicity in the replication sample (n = 13 615). Based on geometric mean CRP (1.93 mg/L) in the replication sample, estimated absolute CRP effects are as follows: for rs6700896, -0.29 mg/L; for rs4537545, -0.22 mg/L; for rs7553007, -0.40 mg/L; for rs1183910, -0.27 mg/L; and for rs4420638, -0.42 mg/L. (To convert CRP to nmol/L, multiply by 9.524.)

tion structure of the specific cohort). For other LOLIPOP data sets, genomic control factors were used to correct for any inflation. No principal components were included for DESIR because the population was recruited from a geographically restricted area.

Statistical software used for genome-wide associations comprised SNPTEST (Genetics Software Suite) version 1.1.3 (in DESIR), and version 1.1.4 (in CoLaus, GEMS, and NFBC); and MACH2QTL version 1.0 (Center for Statistical Genetics) (in LOLIPOP). Results of the separate genome-wide association studies were combined using weighted z scores, and a fixed-rather than random-effects model to maximize discovery, since random-effects estimates are associated with larger variance. Quantile-quantile plots showed good adherence to null expectations ( $\lambda$  for combined data = 1.0625). We used  $P < 5 \times 10^{-8}$  to designate genome-wide significance, taking account of the approximately 1 million independent tests for common variants across the genome.<sup>23</sup> For 5 genetic loci associated with CRP levels at genome-wide significance, we selected the single most closely associated SNP (ie, smallest P value) for replication against CRP.

Using Quanto<sup>24</sup> version 1.2 for quantitative traits, we estimated that the genome-wide association study had 80% power to detect SNPs associated with 0.2% of population variation in CRP levels, or an 11% difference in CRP level per allele copy, at MAF 0.3 and genome-wide level of significance ( $P < 5 \times 10^{-8}$ ).

**Mendelian Randomization Study of Genetic Variants in the CRP Locus and CHD.** We analyzed the relationship of SNP rs7553007 in the CRP locus, the SNP most strongly associated with CRP levels in our data, for association with CHD risk using logistic regression under an additive genetic model as part of a mendelian randomization study. To identify published data on the relationship of CRP variants with CHD, 2 electronic databases (Medline and EMBASE) were searched up to and including November 2008 for all prospective studies (including cohort, nested case-control, and case-cohort studies) and case-control studies, with no threshold sample size. For the search, the MeSH terms *C-reactive protein* and *polymorphism, single nucleotide or polymorphism, genetic or haplotype* in combination with *coronary disease* or *heart disease* were used, and

the search was limited by the terms *human* and *English language*. We also scanned reference lists of previous reports.

Eight studies of 18 cohorts were identified. Two studies<sup>25,26</sup> examining 9 cohorts reported results for a single SNP (SNP rs1130864); for these studies, odds ratios (ORs) were reported under a recessive model comparing homozygotes (TT) for the minor allele with CT/CC genotype, and mean effect on CRP levels was obtained from published ratio of geometric means (1.21).<sup>25,26</sup> For the remaining studies,<sup>8,27-31</sup> we selected SNP rs1205 on the basis of MAF greater than 0.1 and largest per-allele effect size on CRP levels (-0.35 mg/L) reported in the study of CRP variants and CRP levels by Verzilli et al.<sup>32</sup> (To convert CRP to nmol/L, multiply by 9.524.) We used a per-allele OR of rs1205 with CHD where available<sup>27,29</sup> or where this could be estimated directly from the data<sup>8,31</sup>; otherwise, ORs were estimated from averaging published effect sizes for minor allele homozygotes (TT) and heterozygotes (CT) compared with wild type (CC).<sup>28,30</sup> We estimated standard errors of the effect sizes of CRP variants on CHD from the reported 95% confidence intervals (CIs), assuming normality.

**Table 2.** Relationships Between Most Associated SNPs in the 5 Genetic Loci Associated With CRP Levels and Cardiovascular Risk Factors in Replication Sample (LOLIPOP, n = 13 615) From Regression Analyses Adjusted for Age, Sex, and Ethnic Group Under an Additive Genetic Model<sup>a</sup>

| Cardiovascular Risk Factors | SNP (Locus)               |         |                          |         |                          |         |                          |         |                           |                       |
|-----------------------------|---------------------------|---------|--------------------------|---------|--------------------------|---------|--------------------------|---------|---------------------------|-----------------------|
|                             | rs6700896 (LEPR)          | P Value | rs4537545 (IL6R)         | P Value | rs7553007 (CRP)          | P Value | rs1183910 (HNF1A)        | P Value | rs4420638 (APOE-C1-C2)    | P Value               |
| Weight, kg                  | -0.44<br>(-0.78 to -0.10) | .01     | 0.19<br>(-0.16 to 0.54)  | .29     | 0.10<br>(-0.27 to 0.46)  | .60     | 0.03<br>(-0.31 to 0.37)  | .87     | 0.16<br>(-0.31 to 0.64)   | .49                   |
| Body mass index             | -0.12<br>(-0.23 to -0.00) | .05     | 0.01<br>(-0.11 to 0.13)  | .83     | 0.00<br>(-0.12 to 0.13)  | .98     | -0.04<br>(-0.16 to 0.07) | .46     | 0.01<br>(-0.15 to 0.18)   | .86                   |
| Systolic BP, mm Hg          | 0.03<br>(-0.38 to 0.43)   | .89     | 0.07<br>(-0.34 to 0.49)  | .74     | -0.02<br>(-0.45 to 0.41) | .93     | 0.02<br>(-0.39 to 0.43)  | .93     | -0.38<br>(-0.94 to 0.19)  | .19                   |
| Diastolic BP, mm Hg         | 0.10<br>(-0.14 to 0.35)   | .39     | 0.14<br>(-0.11 to 0.39)  | .27     | -0.19<br>(-0.45 to 0.07) | .15     | -0.04<br>(-0.28 to 0.21) | .77     | -0.09<br>(-0.43 to 0.24)  | .58                   |
| Cholesterol, mg/dL          | 0.18<br>(-0.81 to 1.18)   | .72     | 0.00<br>(-1.03 to 1.02)  | .99     | -0.78<br>(-1.84 to 0.29) | .15     | 1.24<br>(0.23 to 2.25)   | .02     | 6.27<br>(4.88 to 7.66)    | $1.0 \times 10^{-18}$ |
| Triglycerides, mg/dL        | -0.34<br>(-2.85 to 2.18)  | .79     | -2.21<br>(-4.80 to 0.39) | .10     | 0.12<br>(-2.57 to 2.82)  | .93     | -0.78<br>(-3.33 to 1.77) | .55     | 11.05<br>(7.54 to 14.56)  | $7.0 \times 10^{-10}$ |
| HDL cholesterol, mg/dL      | 0.15<br>(-0.14 to 0.44)   | .30     | -0.10<br>(-0.40 to 0.20) | .52     | -0.01<br>(-0.32 to 0.30) | .94     | 0.30<br>(0.01 to 0.59)   | .05     | -1.17<br>(-1.57 to -0.76) | $1.6 \times 10^{-6}$  |
| LDL cholesterol, mg/dL      | 0.14<br>(-0.69 to 0.97)   | .75     | 0.41<br>(-0.45 to 1.27)  | .35     | -0.65<br>(-1.54 to 0.24) | .15     | 1.22<br>(0.38 to 2.07)   | .004    | 5.77<br>(4.60 to 6.93)    | $3.5 \times 10^{-22}$ |
| Diabetes mellitus           | 1.05<br>(0.97 to 1.13)    | .26     | 0.94<br>(0.86 to 1.02)   | .12     | 1.03<br>(0.94 to 1.12)   | .53     | 1.05<br>(0.97 to 1.14)   | .21     | 1.01<br>(0.90 to 1.13)    | .91                   |

Abbreviations: BP, blood pressure; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SNP, single-nucleotide polymorphism.  
<sup>a</sup>Data presented as unit change (continuous traits) or odds ratio (diabetes mellitus) and 95% confidence interval per copy of minor allele.


Estimated ORs for CRP variants on CHD were converted to a common scale by standardizing to 20% lower CRP, ie, the approximate effect per minor allele of rs7553007 on CRP levels. Results were combined across studies by SNP and across the 3 SNPs weighted by the inverse of variance. We used 95% CIs and assessed heterogeneity with standard  $\chi^2$  statistics, expressed as  $I^2$ , the proportion of variability between studies due to heterogeneity.<sup>33</sup> In the absence of heterogeneity, we used a fixed-effects model.

We also investigated the 3-way associations between CRP genetic variants, CRP levels, and CHD in prospective studies that reported all 3 sets of data in the same cohorts.<sup>25-27,30</sup> We did not include retrospective (case-control) studies since these could be biased by treatment effects.<sup>34</sup>

**Comparison of the Result of the Mendelian Randomization Study With Meta-analysis of the CRP-CHD Relationship.** We compared the result from our mendelian randomization study with that predicted from a meta-analysis of the obser-


vatational studies of CRP levels and CHD.<sup>4,5,8,26,35-61</sup> This was obtained from a systematic review of the CRP-CHD relationship published by Shah et al,<sup>5</sup> updated with all studies published from August 2007 until November 2008. For the search, the MeSH terms *C-reactive protein* and *CRP* in combination with *coronary*, *coronary heart disease*, *CHD*, and *CVD* were used, and the search was limited by the terms *human* and *English language*. Studies in which total mortality was the only outcome reported were excluded; if more than 1 article was published on the same cohort

**Figure 2.** Results of Mendelian Randomization Experiment of rs7553007 in the CRP Locus (Present Study) With rs1130864 and rs1205 From Published Studies



Numbers totaled 28 112 cases with coronary heart disease and 100 823 controls. Effects are given as odds ratios (ORs) and 95% confidence intervals (CIs) per 20% lower C-reactive protein (CRP) level. E indicates European; IA, Indian Asian; SNP, single-nucleotide polymorphism.

**Figure 3.** Associations of SNPs rs1130864 and rs1205 With CRP Levels, CRP Levels With CHD, and SNPs With CHD



Prospective studies were included that reported all 3 analyses. CHD indicates coronary heart disease; CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; SNPs, single-nucleotide polymorphisms.

or population, the most recent one was used in the meta-analysis.

Five new population studies were identified from 4 reports.<sup>8,26,35,36</sup> Risk ratios for CHD associated with CRP levels (logarithmically transformed) were extracted from each study. Two studies were excluded: one<sup>62</sup> that cited risk ratios per unit increase in CRP (ie, not logarithmically transformed) and one<sup>63</sup> that did not provide CIs for the association of CRP with CHD. The studies reported risk ratios based on different comparisons of CRP (tertiles, quintiles, or quartiles) or as differences in risk for a given increase in CRP level; these were converted to a common unit of 1 SD change.


The risk ratio per standard deviation change was converted to per 20% lower CRP by multiplying coefficients (and 95% CIs) on the logarithmic scale by -0.223, assuming that a 20% reduction in CRP is equivalent to a 0.223 SD reduction in log CRP.

Multivariate-adjusted risk ratios, controlled for conventional cardiovascular risk factors, were used when available; 2 studies reported risk ratios adjusted for age only and age and smoking only.<sup>37,38</sup> Because of significant heterogeneity, random-effects meta-analysis was used to combine the risk ratios from the individual studies. The overall OR for CHD was used to test the observed vs predicted association of CRP

variants with CHD, standardized to 20% lower CRP level.

**Genetic Association of Variants Outside the CRP Locus and CHD.** The relationships with risk of CHD of the most associated SNP in the 4 genetic loci other than the CRP locus in our data were analyzed by logistic regression under an additive genetic model. Results were combined across studies by SNP using a fixed-effects model weighted by the inverse of variance because there was no significant heterogeneity. By use of the Genetic Power Calculator,<sup>64</sup> we estimated that the genetic association study with CHD had 80% power to detect an OR of 1.04 per allele copy at  $P < .05$  and MAF 0.3.

**Figure 4.** Meta-analysis of the Relationship of CRP Levels With CHD From Prospective Observational Studies



A random-effects estimate is presented; the fixed-effects estimate has an odds ratio (OR) of 0.95 (95% confidence interval [CI], 0.94-0.96). Effects are given as ORs and 95% CIs per 20% lower C-reactive protein (CRP) level. For cohort studies, number of "controls" represents the number of event-free individuals. Number of controls was not available for ARIC.<sup>54</sup> CHD indicates coronary heart disease; C, cohort; CC, case-cohort; NCC, nested case-control.

With the exception of the genome-wide association analyses described here, statistical analyses were done with Stata version 10 (StataCorp, College Station, Texas) or SAS version 9.1 (SAS Institute Inc, Cary, North Carolina). A significance level of  $P < .05$  was used; all tests were 2-sided.


Ethics approval was obtained locally for each of the participating cohorts for analyses of genetic markers of cardiovascular disease risk. No additional ethics approvals were required for this study.

**RESULTS**  
**Genome-Wide Association and Replication Study for CRP**

We found 160 SNPs to be associated with CRP levels at  $P < 5 \times 10^{-8}$ , distributed in the following 5 loci: *LEPR* (GeneID 3953, GenBank NC\_000001.9, region 65658906 to 65875410), *IL6R* (GeneID 3570, GenBank NC\_000001.9, region 152644293 to 152706812), *CRP* (GeneID 1401, GenBank NC\_000001.9, region 157951003 to 157948703), *HNF1A* (GeneID 6927, GenBank

NC\_000012.10, region 119900932 to 119924698) and *APOE-CI-CII* (GeneID 348, 341, 344, GenBank NC\_000019.8, region 50100879 to 50104490). A Manhattan plot of results from the combined analysis of genome-wide association data is shown in FIGURE 1. Genomic context and  $P$  values for the most associated SNP at each of the 5 loci are shown in TABLE 1. The association of these SNPs with CRP levels was confirmed in replication testing (all  $P \leq 10^{-10}$ ); for all 5 SNPs, the minor al-

**Figure 5.** Associations of SNPs in *LEPR* (rs6700896), *IL6R* (rs4537545), and *HNF1A* (rs1183910) Loci and *APOE-CI-CII* (rs4420638) Cluster in the Genetic Association Study With CHD



Effects are given as odds ratios (ORs) and 95% confidence intervals (CIs) per copy of minor allele. CHD indicates coronary heart disease; E, European; IA, Indian Asian; SNPs, single-nucleotide polymorphisms.



lele was associated with reduced levels of CRP (Table 1). For the most associated SNP in the *CRP* locus (rs7553007), CRP levels were lower by 21% (95% CI, -23.4% to -17.9%) per minor allele. For the other 4 SNPs, per-minor-allele differences in CRP levels ranged from -11.5% (95% CI, -14.4% to -8.5%) for SNP rs4537545 in *IL6R* to -21.8% (95% CI, -25.3% to -18.1%) for SNP rs4420638 in the *APOE-CI-CII* cluster (Table 1).

In the replication study (LOLIPOP), the percent variance of CRP explained ranged from 0.2% (SNP rs1183910 in *HNFI A*) to 1.3% (rs7553007 in the *CRP* locus). SNP rs4420638 in the *APOE-CI-CII* cluster was strongly associated with total cholesterol (6.27 mg/dL; 95% CI, 4.88 to 7.66 mg/dL; per minor allele), low-density lipoprotein (LDL) cholesterol (5.77 mg/dL; 95% CI, 4.60 to 6.93 mg/dL; per minor allele), triglycerides (11.05 mg/dL; 95% CI, 7.54 to 14.56 mg/dL; per minor allele) and high-density lipoprotein (HDL) cholesterol (-1.17 mg/dL; 95% CI, -1.57 to -0.76 mg/dL; per minor allele) (TABLE 2). SNP rs1183910 in *HNFI A* was associated with total cholesterol (1.24 mg/dL; 95% CI, 0.23 to 2.25 mg/dL; per minor allele), LDL cholesterol (1.22 mg/dL; 95% CI, 0.38 to 2.07 mg/dL; per minor allele), and HDL cholesterol (0.30 mg/dL; 95% CI, 0.01 to 0.59 mg/dL; per minor allele). (To convert total, LDL, and HDL cholesterol to mmol/L, multiply by 0.0259; to convert triglycerides to mmol/L, multiply by 0.0113.) SNP rs6700896 in *LEPR* was associated with weight (-0.44 kg; 95% CI, -0.78 to -0.10 kg; per minor allele) and body mass index (-0.12; 95% CI, -0.23 to -0.00; per minor allele; body mass index is calculated as weight in kilograms divided by height in meters squared). The remaining 2 SNPs were not significantly related to any of the phenotypes tested (Table 2).

### Mendelian Randomization Study of Genetic Variants in the *CRP* Locus and CHD

FIGURE 2 shows the results of the mendelian randomization experiment of CHD with variants in the *CRP* locus: SNP rs7553007 (our data) and pub-

lished data for SNPs rs1130864 and rs1205 for 18 cohorts. SNP rs7553007 was not significantly associated with CHD; the estimated OR was 0.98 (95% CI, 0.94 to 1.01) per 20% lower CRP level. For rs1130864, the OR was 1.00 (95% CI, 0.86 to 1.15), and for rs1205, the OR was 1.03 (95% CI, 0.99 to 1.07). There was no association of CHD with *CRP* variants (per 20% lower CRP level) when results for all 3 SNPs were combined (OR, 1.00; 95% CI, 0.97 to 1.02) (Figure 2).

In the 3-way comparison of *CRP* genetic variants, CRP levels, and CHD risk reported in prospective studies, there was significant association of *CRP* variants with CRP levels, and CRP levels with CHD, but not *CRP* variants with CHD (FIGURE 3).

### Comparison of the Result of the Mendelian Randomization Study With Meta-analysis of the *CRP*-CHD Relationship

The meta-analysis of observational studies of CRP levels and CHD gave a predicted OR of 0.94 (95% CI, 0.94 to 0.95) per 20% lower CRP level (FIGURE 4). This is significantly different from the estimated effect on CHD (OR, 1.00) of genetically determined differences in CRP levels obtained from our mendelian randomization study ( $z = -3.45$ ,  $P < .001$ ).

### Genetic Association of Variants Outside the *CRP* Locus and CHD

Minor alleles of SNP rs6700896 in *LEPR* and rs4420638 in *APOE-CI-CII* cluster were associated with significantly increased risk of CHD (OR, 1.06; 95% CI, 1.02 to 1.09; and OR, 1.16; 95% CI, 1.12 to 1.21; respectively), and SNP rs4537545 in *IL6R* with a decreased risk of CHD (OR, 0.94; 95% CI, 0.91 to 0.97), while SNP rs1183910 in *HNFI A* was not significantly associated with CHD (FIGURE 5). The effects of SNPs rs6700896 in *LEPR* and rs4420638 in the *APOE-CI-CII* cluster on CHD were in the opposite direction to that predicted from the relationship of CRP levels with CHD (Figure 4); for rs4420638 the finding was consistent with the ef-

fects on blood lipid concentrations (Table 2).

### COMMENT

The present genome-wide association study confirms the associations of common genetic variants in the *LEPR*, *IL6R*, *CRP*, and *HNFI A* loci and *APOE-CI-CII* cluster with CRP levels.<sup>65,66</sup> However, the minor allele of SNP rs7553007 and other variants in the *CRP* locus included in our mendelian randomization study were not associated with CHD risk.

The variants included in our mendelian randomization study are associated with approximately 20% lower CRP levels,<sup>32</sup> corresponding to a 6% reduction in CHD risk predicted by the meta-analysis of observational studies of CHD risk. The lack of association with CHD of genetic variants in the *CRP* locus suggests that the observational data linking CRP levels and CHD may be confounded by association with other CHD risk factors, or reflect a secondary inflammatory response associated with atherosclerosis (reverse causation), rather than indicate a causal relationship.

Our analysis of SNP rs7553007 with CHD risk includes more cases than all previously published studies of *CRP* variants and CHD combined,<sup>8,25-31</sup> yielding with the 2 published SNPs a total of more than 28 000 cases and 100 000 controls for the mendelian randomization study. The largest previous study, of 3 cohorts in Copenhagen, included 6545 cases.<sup>8</sup> In addition to rs1205 included in our mendelian randomization study, it provided data on the triallelic SNP rs3091244 and SNP rs3093077, both having variants with larger effects on CRP levels (20%-30%) than rs1205; however, both variants are rare, and neither was associated with CHD in the Copenhagen study.<sup>8</sup>

The JUPITER trial recently reported a benefit of treatment with rosuvastatin on CHD risk among men and women with elevated CRP levels (2.0 mg/L or higher) and with LDL cholesterol levels below 130 mg/dL.<sup>34</sup> In the treatment group, there was 54% reduction in rates of MI compared with placebo; LDL levels were reduced by 50% and CRP levels by 37%. Although the JUPITER trial demonstrated the benefits

of statin therapy in people with LDL levels below current treatment threshold, the results may simply reflect the benefits of lipid-lowering therapy in people who would not currently be considered for pharmacotherapy, rather than the benefits of CRP lowering per se.<sup>67</sup>

Investigation of genetic variants underlying an intermediate phenotype (such as CRP) has been advocated as a means of discovering new disease susceptibility loci.<sup>10</sup> In our study, minor alleles of SNPs rs6700896 in *LEPR* and rs4420638 in the *APOE-CI-CII* cluster showed significantly increased risk of CHD. However, both variants were associated with reduced levels of CRP (and for SNP rs6700896 in *LEPR*, lower body weight and body mass index), suggesting that the links with CHD are not mediated by CRP. *LEPR* has not previously been reported to increase risk of CHD, although associations of variants in the *APOE-CI-CII* cluster with CHD have been observed.<sup>68,69</sup> While the association of genetic variation in *APOE-CI-CII* with CHD can be explained in large part by its effects on blood lipids, this is not the case for SNP rs6700896 in *LEPR*. SNP rs6700896 is located in intron 19 of *LEPR*, the gene encoding the leptin receptor, a member of the class I cytokine receptor family.<sup>70</sup> *LEPR* is expressed in the hypothalamus and vascular endothelial cells,<sup>71</sup> and *LEPR* signaling has a role in appetite control, weight regulation, glucose homeostasis, blood pressure regulation, and angiogenesis.<sup>70-72</sup> The minor allele of SNP rs4537545 in *IL6R* was also associated with reduced CRP levels and reduced risk of CHD. SNP rs4537545 in *IL6R* is in high linkage disequilibrium ( $r^2=0.96$  in the HapMap CEU reference population) with a nonsynonymous SNP (rs8192284, Asp358Ala) associated with increased *IL6R* expression and alterations of *IL6R* membrane binding,<sup>39</sup> providing a potential mechanism linking rs4537545 to biological function. Further studies will be needed to confirm *LEPR* and *IL6R* as new susceptibility loci for CHD.

Our study has limitations. Because of the relatively small effect of common genetic variants in *CRP* locus on CRP levels, a large sample size is needed to detect

associations with CHD. To combine data across studies in our mendelian randomization study, we assumed a common effect on risk of CHD from different variants in the *CRP* locus by standardizing to a common difference on the log CRP scale. This approach is valid to the extent that the hypothesized effect of *CRP* variants on CHD risk reflects circulating levels of CRP. Although we found no association of *CRP* variants with CHD risk, it is not possible to exclude a small effect, despite the large sample size. However, we can effectively exclude the size of association predicted from observational data on the relationship of CRP levels to CHD. The mendelian randomization approach makes a number of assumptions concerning possible causality. These include the potential for pleiotropic effects of the genetic variants under study (or variants in high linkage disequilibrium with them) giving an alternative pathway to CHD or confounding through associations with disease risk factors.<sup>9</sup> Neither rs7553007 or the other 2 variants included from the *CRP* locus correlate with CHD risk factors,<sup>8,26</sup> satisfying an important condition for a valid mendelian randomization experiment.<sup>9</sup>

In summary, our mendelian randomization study of more than 28 000 cases and 100 000 controls found no association of variants in the *CRP* locus and CHD, arguing against a causal role for CRP in atherosclerosis. Moreover, this study suggests that development of therapeutic strategies targeting specific reductions in plasma levels of CRP are unlikely to be fruitful.

**Author Affiliations:** Faculty of Medicine, Imperial College London, London, United Kingdom (Drs Elliott, Chambers, Zhang, Coin, Ashby, Tzoulaki, Brown, Mt-Isa, Ashby, Froguel, Jarvelin, Scott, and Koener); Institute of Health Science (Dr Jarvelin), Institute of Diagnostics (Dr Ruokonen), and Biocenter Oulu (Dr Jarvelin), University of Oulu, Oulu, Finland; National Institute for Health and Welfare, Oulu (Dr Jarvelin); Clinical Trial Service Unit and Epidemiological Studies Unit (Drs Clarke, Hopewell, Bennett, and Collins), and Department of Cardiovascular Medicine and Wellcome Trust Centre for Human Genetics (Drs Peden, Farrall, and Watkins), University of Oxford, Oxford, United Kingdom; Oxford Centre for Diabetes, Endocrinology and Metabolism and Oxford National Institute for Health Research Biomedical Research Centre, Oxford (Dr McCarthy); Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom (Dr Pelttonen); Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom (Drs Braund and Samani); Departments of Medicine and Human Genetics, McGill University, Montreal, Quebec, Canada (Dr Engert); Leeds Institute for Genetics

and Therapeutics, University of Leeds, Leeds, United Kingdom (Dr Hall); Universität zu Lübeck, Lübeck, Germany (Drs Erdmann and Schunkert); Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada (Dr Anand); Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton (Dr Anand); Department of Medicine, CHUV University Hospital, Lausanne, Switzerland (Drs Vollenweider and Waeber); Center for Neurobehavioral Genetics, University of California at Los Angeles (Dr Freimer); Department of Medicine, Karolinska Institutet, Stockholm, Sweden (Dr Hamsten); and Genetics Division, GlaxoSmithKline, King of Prussia, Pennsylvania (Drs Lim, Waterworth, and Mooser).

**Author Contributions:** Dr Elliott had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Elliott and Chambers contributed equally to this work.

**Study concept and design:** Elliott, Chambers, Scott, Koener.

**Acquisition of data:** Elliott, Chambers, Clarke, Peden, Erdmann, Braund, Engert, Pelttonen, Freimer, Ruokonen, Hamsten, Froguel, Waterworth, Vollenweider, Waeber, Jarvelin, Mooser, Hall, Schunkert, Anand, Collins, Samani, Watkins, Koener.

**Analysis and interpretation of data:** Elliott, Chambers, Zhang, Clarke, Peden, Bennett, Engert, Hopewell, Coin, Ashby, Tzoulaki, Brown, Mt-Isa, McCarthy, Pelttonen, Farrall, Ruokonen, Lim, Jarvelin, Scott, Anand, Samani, Koener.

**Drafting of the manuscript:** Elliott, Chambers, Scott, Koener.

**Critical revision of the manuscript for important intellectual content:** Elliott, Chambers, Zhang, Clarke, Hopewell, Peden, Erdmann, Braund, Engert, Bennett, Coin, Ashby, Tzoulaki, Brown, Mt-Isa, McCarthy, Pelttonen, Freimer, Farrall, Ruokonen, Hamsten, Lim, Froguel, Waterworth, Vollenweider, Waeber, Jarvelin, Mooser, Hall, Schunkert, Anand, Collins, Samani, Watkins, Koener.

**Statistical analysis:** Elliott, Chambers, Zhang, Peden, Bennett, Engert, Hopewell, Coin, Ashby, Tzoulaki, Brown, Mt-Isa, Farrall, Lim, Froguel, Schunkert, Koener.

**Obtained funding:** Chambers, McCarthy, Freimer, Farrall, Hamsten, Froguel, Waterworth, Vollenweider, Waeber, Jarvelin, Mooser, Scott, Hall, Anand, Collins, Watkins, Koener.

**Administrative, technical, or material support:** Elliott, Chambers, Clarke, Peden, Erdmann, Braund, Brown, Mt-Isa, Freimer, Ruokonen, Hamsten, Lim, Waterworth, Vollenweider, Jarvelin, Mooser.

**Study supervision:** Elliott, Chambers, Clarke, Coin, Farrall, Waterworth, Vollenweider, Waeber, Mooser, Samani, Watkins, Koener.

**Financial Disclosures:** None reported.

**Funding/Support:** The Data from an Epidemiological Study on the Insulin Resistance syndrome (DESIR) received support from INSERM, CNAMTS, Lilly, Novartis Pharma, Sanofi-Aventis, the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Ardic Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon, and the European Union (P.F.) (Integrated Project EURO-DIA LSHM-CT-2006-518153 in the Framework Programme 6 [FP06] of the European Community). The Genetic Epidemiology of Metabolic Syndrome (GEMS) study was sponsored in part by GlaxoSmithKline. The German MI Family Study was supported by grants from the Deutsche Forschungsgemeinschaft and the Deutsche Herzstiftung, the National Genome Research Network 2 of the German Federal Ministry of Education and Research, and the Cardiogenics project of the European Union. From the INTERHEART study, Dr Anand holds the Michael G. DeGroot and Heart and Stroke Foundation of Ontario Chair in Population Health and the May Cohen Eli Lilly En-

dowed Chair in Women's Health Research, McMaster University. The INTERHEART study was funded by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Ontario, and the International Clinical Epidemiology Network (INCLIN); through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca, Novartis, Sanofi-Aventis, Knoll Pharmaceuticals [now Abbott], Bristol Myers Squibb, and King Pharma); and by various national bodies in different countries as follows: Chile, Universidad de la Frontera, Sociedad Chilena de Cardiología Filial Sur; Colombia, Colciencias, Ministerio de Salud; Croatia, Croatian Ministry of Science and Technology; Guatemala, Liga Guatemalteca del Corazon; Hungary, Astra Hassle, National Health Science Council, George Gabor Foundation; Iran, Iran Ministry of Health; Italy, Boehringer-Ingelheim; Japan, Sankyo Pharmaceutical Co, Banyu Pharmaceutical Co, Astra Japan; Kuwait, Endowment Fund for Health Development in Kuwait; Pakistan, ATCO Laboratories; Philippines, Philippine Council for Health Research and Development, Pfizer Philippines Foundation, Inc, Astra Pharmaceuticals Inc and the Astra Fund for Clinical Research and Continuing Medical Education, Pharmacia and Upjohn Inc; Poland, Foundation PROCLINICA; Singapore, Singapore National Heart Association; South Africa, Medical Research Council of South Africa, Warner-Parke-Davis Pharmaceuticals, Aventis; Sweden, grant from the Swedish State under the LUA agreement, Swedish Heart and Lung Foundation; Thailand, Heart Association of Thailand, Thailand Research Fund. The International Studies of Infarct Survival (ISIS) trials and epidemiological studies were supported by the manufacturers of the study drugs and by the British Heart Foundation, Medical Research Council, Cancer Research UK, Tobacco Products Research Trust of the UK Department of Health Independent Scientific Committee on Smoking and Health, and Oxford NHS Genetic Knowledge Park. The Lausanne Cohort (CoLaus) study received support from the Giorgi-Cavaglieri Foundation (Toby Johnson, Sven Bergmann), the Université de Lausanne (Jacques S. Beckmann), and grant 3100AO-116323/1 (Sven Bergmann) from the Swiss National Science Foundation (Murielle Bochud). GlaxoSmithKline provided support to build the CoLaus study (Drs Vollenweider and Waeber). This work was supported by GlaxoSmithKline and the Faculty of Biology and Medicine, Université de Lausanne, Lausanne, Switzerland. The London Life Sciences Population (LOLIPOP) received support from grant SP/04/002 from the British Heart Foundation. The 1966 North Finland Birth Cohort received support from grant 5R01HL087679-02 from the National Heart, Lung, and Blood Institute through the STAMPEED program; the Medical Research Council of the United Kingdom; the European Birth Life-Course Study; contract QLGI-CT-2000-01643 from the European Commission "Quality of Life and Management of Living Resources"; the Biocenter Oulu of University of Oulu; the Academy of Finland; and grant 1RL1MH083268-01 from the National Institute of Mental Health. The Precocious Coronary Artery Disease study (PROCARDIS) was funded by the British Heart Foundation, EC Sixth Framework Programme (LSHM33 CT-2007-037273), AstraZeneca AB, and the Knut and Alice Wallenberg Foundation. The Wellcome Trust Case Control Consortium (WTCCC) study received support for recruitment from grants from the British Heart Foundation and the UK Medical Research Council. It also received support from the Wellcome Trust Functional Genomics Initiative in Cardiovascular Genetics. Dr Samani holds a chair funded by the British Heart Foundation.

**Role of the Sponsor:** With the exception of GlaxoSmithKline, whose scientists were involved in the planning, data collection, and analysis for the GEMS and CoLaus studies, funders had no role in the design and conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.

**GEMS Study Investigators:** Philip Barter, PhD; Y. Antero Kesäniemi, PhD; Robert W. Mahley, PhD; Ruth McPherson, FRCP; and Scott M. Grundy, PhD. Dr Waeber was also a GEMS investigator. Detailed information on the GEMS study design, sampling frame, and recruitment procedures has been published previously.<sup>15</sup>

**INTERHEART Study.** The clinical centers are named in the 2004 INTERHEART report (<http://www.thelancet.com/journals/lancet/article/PIIS0140673604170189/abstract>).

**ISIS Study.** A full list of the participating centers and collaborators is given in the ISIS-3 report.<sup>19</sup>

**CoLaus Study Investigators:** Jacques S. Beckmann, Sven Bergmann, Murielle Bochud, Toby Johnson, Kijoung Song, Xin Yuan, and Drs Lim, Mooser, Vollenweider, Waeber, and Waterworth. *Principal investigators:* Drs Mooser and Vollenweider. *Study design:* Jacques S. Beckmann and Drs Mooser, Vollenweider, Waeber, and Waterworth. *Assembly of the cohort:* Dr Waeber. *Data analysis:* Dr Lim. *Project management:* Jacques S. Beckmann, Sven Bergmann, Murielle Bochud, and Drs Mooser, Vollenweider, and Waterworth.

**LOLIPOP Study Investigators:** Drs Chambers, Elliott, Scott, and Kooner. *Principal investigator:* Dr Kooner. *Data analysis:* Drs Chambers and Zhang and Delilah Zabeneh, Robin Walters, Maria de Iorio, and David Balding.

**1966 North Finland Birth Cohort Investigators:** Drs Elliott, Freimer, Jarvelin, McCarthy, and Peltonen and Anna-Liisa Hartikainen and Anneli Pouta. *Data analysis:* Dr Coin and Pimphen Charoen. *Biochemical analysis:* Dr Ruokonen.

**PROCARDIS Investigators:** Drs Clarke, Farrall, Hamsten, Peden, and Watkins and Anuj Goel, Simon C. Heath, G. Mark Lathrop, Udo Seedorf, Ann-Christine Syvänen, and Giovanni Tognoni. *Principal investigator for project:* Dr Watkins. *Principal investigators for collection center:* Drs Clarke and Hamsten and Udo Seedorf and Giovanni Tognoni. *Genotyping:* Simon C. Heath, G. Mark Lathrop, and Ann-Christine Syvänen. *Quality control:* Simon C. Heath. *Data analysis:* Drs Farrall and Peden and Anuj Goel. *Project management:* Drs Peden and Watkins. A full membership list of the PROCARDIS consortium appears online at <http://www.procardis.org>.

**Additional Contributions:** Maria de Iorio, PhD, and Pimphen Charoen, MPhil, Imperial College, London helped with the statistical analyses for this article. They were not compensated for their contributions. In the INTERHEART study, Ron Do, MSC, helped with statistical analyses. Salim Yusuf initiated and, together with the steering committee members, supervised the conduct of the study. Members of the project office of the Population Health Research Institute, Sumathy Rangarajan and Laura Joldersma helped with study coordination, and Changchun Xie, PhD, provided statistical support. ISIS study investigators gratefully acknowledge the patients and their relatives who collaborated, their general practitioners, and the medical and nursing staff from more than 100 hospitals in the United Kingdom. PROCARDIS investigators are grateful to the participants and to the medical and nursing staff who assisted in the project. None of the INTERHEART contributors nor ISIS/PROCARDIS collaborators listed here were compensated for their contributions.

## REFERENCES

- Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet*. 1997;349(9061):1269-1276.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352(16):1685-1695.
- Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. *Nat Clin Pract Cardiovasc Med*. 2005;2(1):29-36.

4. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med*. 2004;350(14):1387-1397.

5. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. *Int J Epidemiol*. 2009;38(1):217-231.

6. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. *Ann Intern Med*. 2006;145(1):21-29.

7. Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. *Nat Clin Pract Nephrol*. 2008;4(5):234-235.

8. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillensen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. *N Engl J Med*. 2008;359(18):1897-1908.

9. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. *PLoS Med*. 2008;5(8):e177.

10. Hunter DJ, Altshuler D, Rader DJ. From Darwin's finches to canaries in the coal mine: mining the genome for new biology. *N Engl J Med*. 2008;358(26):2760-2763.

11. Chambers JC, Elliott P, Zabaneh D, et al. Common genetic variation near MLC4R is associated with waist circumference and insulin resistance. *Nat Genet*. 2008;40(6):716-718.

12. Tzoulaki I, Jarvelin MR, Hartikainen AL, et al. Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: Northern Finland 1966 Birth Cohort Study. *Eur Heart J*. 2008;29(8):1049-1056.

13. Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet*. 2009;41(1):35-46.

14. Yuan X, Waterworth D, Perry J, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. *Am J Hum Genet*. 2008;83(4):520-528.

15. Wyszynski DF, Waterworth DM, Barter PJ, et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). *Am J Cardiol*. 2005;95(2):194-198.

16. Bouatia-Naji N, Rocheleau G, Van Lommel L, et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. *Science*. 2008;320(5879):1085-1088.

17. Farrall M, Green FR, Peden JF, et al. Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. *PLoS Genet*. 2006;2(5):e72.

18. Clarke R, Xu P, Bennett D, et al; International Study of Infarct Survival (ISIS) Collaborators. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. *PLoS Genet*. 2006;2(7):e107.

19. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. *Lancet*. 1992;339(8796):753-770.

20. Samani NJ, Erdmann J, Hall AS, et al; WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. *N Engl J Med*. 2007;357(5):443-453.

21. Schunkert H, Götz A, Braund P, et al; Cardiogenics Consortium. Repeated replication and a prospective meta-analysis of the association between chro-

- mosome 9p21.3 and coronary artery disease. *Circulation*. 2008;117(13):1675-1684.
22. Pare G, Serre D, Brisson D, et al. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. *Am J Hum Genet*. 2007;80(4):673-682.
23. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genet Epidemiol*. 2008;32(4):381-385.
24. Gauderman WJ, Morrison JM. Quanto 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. <http://hydra.usc.edu/gxe>. Accessed December 1, 2008.
25. Casas JP, Shah T, Cooper J, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. *Int J Epidemiol*. 2006;35(4):922-931.
26. Lawlor DA, Harbord RM, Timpson NJ, et al. The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. *PLoS ONE*. 2008;3(8):e3011.
27. Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. *PLoS ONE*. 2008;3(1):e1395.
28. Lange LA, Carlson CS, Hindorf LA, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. *JAMA*. 2006;296(22):2703-2711.
29. Miller DT, Zee RY, Suk Danik J, et al. Association of common CRP gene variants with CRP levels and cardiovascular events. *Ann Hum Genet*. 2005;69(6):623-638.
30. Kardys I, de Maat MPM, Uitterlinden AG, Hofman A, Witteman JC. C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. *Eur Heart J*. 2006;27(11):1331-1337.
31. Chen J, Zhao J, Huang J, Su S, Qiang B, Gu D. -717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study. *J Mol Med*. 2005;83(1):72-78.
32. Verzilli C, Shah T, Casas JP, et al. Bayesian meta-analysis of genetic association studies with different sets of markers. *Am J Hum Genet*. 2008;82(4):859-872.
33. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558.
34. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein levels. *N Engl J Med*. 2008;359(21):2195-2207.
35. Hung J, Knuiman MW, Divitini ML, Langton PE, Chapman CL, Beilby JP. C-reactive protein and interleukin-18 levels in relation to coronary heart disease: prospective cohort study from Busselton Western Australia. *Heart Lung Circ*. 2008;17(2):90-95.
36. Arima H, Kubo M, Yonemoto K, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. *Arterioscler Thromb Vasc Biol*. 2008;28(7):1385-1391.
37. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. *Circulation*. 2000;101(3):252-257.
38. Störk S, Feelders RA, van den Beld AW, et al. Prediction of mortality risk in the elderly. *Am J Med*. 2006;119(6):519-525.
39. Rafiq S, Fraying TM, Murray A, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. *Genes Immun*. 2007;8(7):552-559.
40. Erbel R, Möhlenkamp S, Lehmann N, et al; Heinz Nixdorf Recall Study Investigative Group. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. *Atherosclerosis*. 2008;197(2):662-672.
41. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med*. 1997;336(14):973-979.
42. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. *Am J Epidemiol*. 1996;144(6):537-547.
43. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. *BMJ*. 2000;321(7255):199-204.
44. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *JAMA*. 2005;294(3):326-333.
45. Luc G, Bard J-M, Juhan-Vague I, et al; PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. *Arterioscler Thromb Vasc Biol*. 2003;23(7):1255-1261.
46. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. *N Engl J Med*. 2004;351(25):2599-2610.
47. Koenig W, Khuseynova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Arterioscler Thromb Vasc Biol*. 2006;26(12):2745-2751.
48. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. *JAMA*. 2002;288(8):980-987.
49. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. *J Thromb Haemost*. 2007;5(9):1795-1800.
50. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2002. *Atherosclerosis*. 2006;187(2):415-422.
51. De Backer J, Mak R, De Bacquer D, et al. Parameters of inflammation and infection in a community based case-control study of coronary heart disease. *Atherosclerosis*. 2002;160(2):457-463.
52. Sattar N, Murray HM, McConnachie A, et al; PROSPER Study Group. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). *Circulation*. 2007;115(8):981-989.
53. Lowe GDO, Sweetnam PM, Yarnell JWG, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. *Arterioscler Thromb Vasc Biol*. 2004;24(10):1957-1962.
54. Folsom AR, Aleksic N, Cellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 2002;144(2):233-238.
55. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. *J Clin Epidemiol*. 2002;55(5):445-451.
56. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. *Circulation*. 2005;112(1):25-31.
57. Packard CJ, O'Reilly DSJ, Caslake MJ, et al; West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. *N Engl J Med*. 2000;343(16):1148-1155.
58. Jager A, van Hinsbergh VWM, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn study. *Arterioscler Thromb Vasc Biol*. 1999;19(12):3071-3078.
59. Wilson PWF, Nam BH, Pencina M, D'Agostino RB Sr, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. *Arch Intern Med*. 2005;165(21):2473-2478.
60. van der Meer IM, de Maat MPM, Kiliaan AJ, van der Kuip DAM, Hofman A, Witteman JCM. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam study. *Arch Intern Med*. 2003;163(11):1323-1328.
61. St-Pierre AC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men: a 13-year follow-up of the Quebec Cardiovascular Study. *Atherosclerosis*. 2005;182(2):315-321.
62. Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. *J Hypertens*. 1998;16(4):537-541.
63. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. *Arch Intern Med*. 2006;166(13):1368-1373.
64. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics*. 2003;19(1):149-150.
65. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEP, HNF1A, IL6R, and GSKR associate with plasma C-reactive protein: the Women's Genome Health Study. *Am J Hum Genet*. 2008;82(5):1185-1192.
66. Reiner AP, Barber MJ, Guan Y, et al. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. *Am J Hum Genet*. 2008;82(5):1193-1201.
67. Hlatky MA. Expanding the orbit of primary prevention: moving beyond JUPITER. *N Engl J Med*. 2008;359(21):2280-2282.
68. Wang C, Zhou X, Ye S, et al. Combined effects of apoE-CI-CII cluster and LDL-R gene polymorphisms on chromosome 19 and coronary artery disease risk. *Int J Hyg Environ Health*. 2006;209(3):265-273.
69. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet*. 2008;40(2):161-169.
70. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. *Annu Rev Physiol*. 2008;70:537-556.
71. Sierra-Honigsmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. *Science*. 1998;281(5383):1683-1686.
72. Rosmond R, Chagnon YC, Holm G, et al. Hypertension in obesity and the leptin receptor gene locus. *J Clin Endocrinol Metab*. 2000;85(9):3126-3131.